Exploring uterine fibroids and its treatment in current scenario

Rajni Yadav,Isotou Drammeh,Mahendra Kumar Sahu
DOI: https://doi.org/10.18231/j.ijcaap.2023.025
2023-11-03
IP International Journal of Comprehensive and Advanced Pharmacology
Abstract:Uterine Fibroids (leiomyoma) are made of muscle cells and other grow tissues grow in and around of the wall of the uterus. Uterine fibroids benign tumors in women reproduction age worldwide. Many are discovered incidentally on clinically examination. Approximately 30% of women with uterine fibroids will present with severe symptoms, which can include abdominal uterine bleeding, anemia, pelvic pain and constipation. Infertility and recurrent miscarriage may also be symptoms of fibroids, depending on their location and size, especially for sub mucous and intramural myelomas distorting the uterine cavity. Current option for symptomatic fibroid treatment includes expectant medical and surgical management radiology procedures. Ultrasound can be done, when a patient is symptomatic of uterine fibroids. Fibroids are generally classified by their location; intramural fibroids, subserosal fibroids, submucosal fibroids. The cause of uterine fibroids is unknown, But research and clinical experience proposes that genetics, hormonal imbalance, other growth factor and extracellular matrix accumulation could be the contributing factors .Although uterine fibroids are usually not dangerous, they can cause discomfort and lead to complication such as, drop in red blood cell (anemia) which causes fatigue from heavy bleeding. Our aim is to highlight the new treatments and advancements in treating uterine fibroids. Later we have also highlighted the future advancements and innovations that are used in developed countries for same.
What problem does this paper attempt to address?